Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. develops and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Company news centers on its advanced ceramics platform, FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, OsseoSculpt™ biologic, and SiNERGY™ silicon nitride/PEEK composite materials for patient-specific implant applications.
Recurring updates also cover commercialization milestones, first-in-human use of SINTX implants, strategic supply and private-label agreements, patent activity in antipathogenic materials, capital actions, operating efficiencies, and management or board changes. The company’s updates frame its current focus around medical-device applications, orthopedic and spine markets, U.S.-based manufacturing, and partnerships that extend the use of silicon nitride biomaterials.
SINTX Technologies (NASDAQ: SINT) announced promising preliminary results from a controlled study showing that their sintered silicon nitride powder inactivates the SARS-CoV-2 virus. The findings align with known antibacterial properties of silicon nitride and efficacy against similar viruses. CEO Dr. Sonny Bal emphasized ongoing independent testing to validate these results. SINTX is dedicated to rigorous R&D verification. However, they caution investors against assuming commercial effectiveness until further data is available.